Kara Follmann, PhD Pfizer, Inc.

Dr. Kara Follmann received her Ph.D. in Biochemistry from the Philipps University in Marburg, Germany. After that she completed a post-doctorate assignment at Aventis Research & Technology studying the regulation of proteins by active pharmaceutical substances to predict their mode of action at a protein level (Proteomics). She then moved to Regulatory Affairs / Chemistry, Manufacturing and Controls (CMC) and is currently the Head of Pfizer’s Essential Health Brands CMC group. She has more than 15 years of global CMC experience across the lifecycle and a variety of pharmatherapeutic dosage forms.